Evidence map›Paper›PMID 38003453›Full record

ReviewInternational journal of molecular sciences2023

Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.

Kazuharu Furutani

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. A hERG Blocker Facilitates KbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Cardiac Arrhythmia: Molecular Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kazuharu FurutaniDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, 180 Nishihama-Boji, Yamashiro-cho, Tokushima 770-8514, Japan.ORCID 0000-0002-9680-2205
Tokushima Bunri University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 21K06812
6 · The paper itself

Abstract

Modulation of the human Ether-à-go-go-Related Gene (hERG) channel, a crucial voltage-gated potassium channel in the repolarization of action potentials in ventricular myocytes of the heart, has significant implications on cardiac electrophysiology and can be either antiarrhythmic or proarrhythmic. For example, hERG channel blockade is a leading cause of long QT syndrome and potentially life-threatening arrhythmias, such as

Indexed as

Ether-A-Go-Go Potassium ChannelsPotassium Channel BlockersAction PotentialsAnti-Arrhythmia AgentsArrhythmias, CardiacERG1 Potassium ChannelHumansMyocytes, CardiacAnti-Arrhythmia AgentsERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsPotassium Channel Blockersdrug-induced arrhythmiashERG channelIKrmolecular pharmacologystructural model

Identifiers

PMID38003453
PMCPMC10671758
OpenAlexW4388630397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.